Selective O-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung

Allison Fryer, Yuh Chin Huang, Gopna Rao, David Jacoby, Edward Mancilla, Richard Whorton, Claude A. Piantadosi, Thomas Kennedy, John Hoidal

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Heparin has potential use as an antiinflammatory treatment in many lung diseases but its therapeutic use is limited by inherent anticoagulant activity. The anticoagulant nature of heparin can be eliminated by a number of chemical treatments, but often not without loss of other important pharmacological activities. Lyophilization of porcine mucosal heparin under extreme alkaline conditions (pH ≤ 13) produces a nonanticoagulant heparin remarkable for the selective loss of only 2-O and 3-O sulfates, leaving 6-O and N-sulfates intact. In contrast to the commonly used nonanticoagulant analog N-desulfated, N-reacetylated heparin, selectively O-desulfated heparin retains potent activity as an inhibitor of the cationic neutrephil proteases human leukocyte elastase and cathepsin G, both in vitro and in vivo. Selectively O-desulfated heparin also inhibits complement lysis of erythrocytes, prevents ischemia-reperfusion [injury of the lung, remains a potent antiproliferative treatment for cultured airway smooth muscle and normalizes altered neuronal M2 muscarinic receptor sensitivity and bronchial hyperreactivity after antigen challenge. These retained pharmacologic properties suggest possible use of this new nonanticoagulant heparin for the treatment of a variety of lung disorders.

Original languageEnglish (US)
Pages (from-to)208-219
Number of pages12
JournalJournal of Pharmacology and Experimental Therapeutics
Volume282
Issue number1
StatePublished - Jul 1997
Externally publishedYes

Fingerprint

Heparin
Pharmacology
Lung
Anticoagulants
Sulfates
Muscarinic M2 Receptors
Cathepsin G
Bronchial Hyperreactivity
Leukocyte Elastase
Freeze Drying
Therapeutic Uses
Therapeutics
Reperfusion Injury
Lung Diseases
Smooth Muscle
Peptide Hydrolases
Anti-Inflammatory Agents
Swine
Erythrocytes
Antigens

ASJC Scopus subject areas

  • Pharmacology

Cite this

Selective O-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung. / Fryer, Allison; Huang, Yuh Chin; Rao, Gopna; Jacoby, David; Mancilla, Edward; Whorton, Richard; Piantadosi, Claude A.; Kennedy, Thomas; Hoidal, John.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 282, No. 1, 07.1997, p. 208-219.

Research output: Contribution to journalArticle

Fryer, A, Huang, YC, Rao, G, Jacoby, D, Mancilla, E, Whorton, R, Piantadosi, CA, Kennedy, T & Hoidal, J 1997, 'Selective O-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung', Journal of Pharmacology and Experimental Therapeutics, vol. 282, no. 1, pp. 208-219.
Fryer, Allison ; Huang, Yuh Chin ; Rao, Gopna ; Jacoby, David ; Mancilla, Edward ; Whorton, Richard ; Piantadosi, Claude A. ; Kennedy, Thomas ; Hoidal, John. / Selective O-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung. In: Journal of Pharmacology and Experimental Therapeutics. 1997 ; Vol. 282, No. 1. pp. 208-219.
@article{cd3b7bebc4414229bd02377e2e45bc9d,
title = "Selective O-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung",
abstract = "Heparin has potential use as an antiinflammatory treatment in many lung diseases but its therapeutic use is limited by inherent anticoagulant activity. The anticoagulant nature of heparin can be eliminated by a number of chemical treatments, but often not without loss of other important pharmacological activities. Lyophilization of porcine mucosal heparin under extreme alkaline conditions (pH ≤ 13) produces a nonanticoagulant heparin remarkable for the selective loss of only 2-O and 3-O sulfates, leaving 6-O and N-sulfates intact. In contrast to the commonly used nonanticoagulant analog N-desulfated, N-reacetylated heparin, selectively O-desulfated heparin retains potent activity as an inhibitor of the cationic neutrephil proteases human leukocyte elastase and cathepsin G, both in vitro and in vivo. Selectively O-desulfated heparin also inhibits complement lysis of erythrocytes, prevents ischemia-reperfusion [injury of the lung, remains a potent antiproliferative treatment for cultured airway smooth muscle and normalizes altered neuronal M2 muscarinic receptor sensitivity and bronchial hyperreactivity after antigen challenge. These retained pharmacologic properties suggest possible use of this new nonanticoagulant heparin for the treatment of a variety of lung disorders.",
author = "Allison Fryer and Huang, {Yuh Chin} and Gopna Rao and David Jacoby and Edward Mancilla and Richard Whorton and Piantadosi, {Claude A.} and Thomas Kennedy and John Hoidal",
year = "1997",
month = "7",
language = "English (US)",
volume = "282",
pages = "208--219",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Selective O-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung

AU - Fryer, Allison

AU - Huang, Yuh Chin

AU - Rao, Gopna

AU - Jacoby, David

AU - Mancilla, Edward

AU - Whorton, Richard

AU - Piantadosi, Claude A.

AU - Kennedy, Thomas

AU - Hoidal, John

PY - 1997/7

Y1 - 1997/7

N2 - Heparin has potential use as an antiinflammatory treatment in many lung diseases but its therapeutic use is limited by inherent anticoagulant activity. The anticoagulant nature of heparin can be eliminated by a number of chemical treatments, but often not without loss of other important pharmacological activities. Lyophilization of porcine mucosal heparin under extreme alkaline conditions (pH ≤ 13) produces a nonanticoagulant heparin remarkable for the selective loss of only 2-O and 3-O sulfates, leaving 6-O and N-sulfates intact. In contrast to the commonly used nonanticoagulant analog N-desulfated, N-reacetylated heparin, selectively O-desulfated heparin retains potent activity as an inhibitor of the cationic neutrephil proteases human leukocyte elastase and cathepsin G, both in vitro and in vivo. Selectively O-desulfated heparin also inhibits complement lysis of erythrocytes, prevents ischemia-reperfusion [injury of the lung, remains a potent antiproliferative treatment for cultured airway smooth muscle and normalizes altered neuronal M2 muscarinic receptor sensitivity and bronchial hyperreactivity after antigen challenge. These retained pharmacologic properties suggest possible use of this new nonanticoagulant heparin for the treatment of a variety of lung disorders.

AB - Heparin has potential use as an antiinflammatory treatment in many lung diseases but its therapeutic use is limited by inherent anticoagulant activity. The anticoagulant nature of heparin can be eliminated by a number of chemical treatments, but often not without loss of other important pharmacological activities. Lyophilization of porcine mucosal heparin under extreme alkaline conditions (pH ≤ 13) produces a nonanticoagulant heparin remarkable for the selective loss of only 2-O and 3-O sulfates, leaving 6-O and N-sulfates intact. In contrast to the commonly used nonanticoagulant analog N-desulfated, N-reacetylated heparin, selectively O-desulfated heparin retains potent activity as an inhibitor of the cationic neutrephil proteases human leukocyte elastase and cathepsin G, both in vitro and in vivo. Selectively O-desulfated heparin also inhibits complement lysis of erythrocytes, prevents ischemia-reperfusion [injury of the lung, remains a potent antiproliferative treatment for cultured airway smooth muscle and normalizes altered neuronal M2 muscarinic receptor sensitivity and bronchial hyperreactivity after antigen challenge. These retained pharmacologic properties suggest possible use of this new nonanticoagulant heparin for the treatment of a variety of lung disorders.

UR - http://www.scopus.com/inward/record.url?scp=0030881464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030881464&partnerID=8YFLogxK

M3 - Article

C2 - 9223556

AN - SCOPUS:0030881464

VL - 282

SP - 208

EP - 219

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -